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Summary
The aim of the experiments described in thesis was to investigate the in-vitro
cytotoxicity of two groups of sesquiterpene lactones (SQLs) towards tumour cells. One
group of SQLs containing Michael-addition sites (MAS), and another group having
endoperoxide moieties. MAS-containing compounds are known to bind to free sulphydryl
groups on proteins. This mechanism explains the cytotoxic action towards cells. The
endoperoxide bridge-containing artemisinin and its derivatives are used to treat malaria.
Reactive degradation products are thought to kill malaria parasites (see Chapter 1). Based
on this potentially reactive structure, we investigated the cytotoxicity of artemisinin and
derivatives towards tumour cells, with the ultimate goal to obtain a "lead" for new
anticancer compounds against tumours in humans.
Chapter 2 describes two methods for measuring cytotoxicity. The cytotoxicity of
artemisinin and some derivatives to a murine Ehrlich ascites tumour cells and a human
HeLa 53 cancer cell line was determined using the MTT and the clonogenic assay. The
MTT assay cannot distinguish between growth inhibition and cell killing, while the
clonogenic assay detects actual cell death. The use of both assays to test a certain
compound may provide information on the mode of its cytotoxicity (i.e. growth inhibition
versus cell killing). The endoperoxides artemisinin and the dirner of dihydroartemisinin
showed much higher cytotoxicity in the MTT assay as compared to the clonogenic assay.
Thus, these compounds mainly induced growth inhibition. Artemisitene and
eupatoriopicrin, which possess MAS, are able to kill cells. Both tests yielded comparable
results. For the reference compounds cisplatin and doxorubicin the MTT assay showed
lower cytotoxicity than the clonogenic assay. This may be explained by "delayed" cell
death. The duration of the MTT assay is shorter than that of the clonogenic assay. Cells
that will not form a colony in the clonogenic assay may still convert MTT.
Chapter 3 deals with SQLs with MAS. The study describes the cytotoxicity of 21
helenanolide-type SQLs to an Ehrlich ascites tumour cell clone (EN2). Srructure-
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cytotoxicity relationships were deternined with respect to the three-dimensional structures
of the compounds as visualized by molecular modelling software. We demonstrated that
steric effects might be an important factor for the extent of cytotoxicity of MAS-
containing SQLs.
Chapter 4 contains a report on the investigation of the stability of artemisinin in
the aqueous environment of the in-vitro tumour-cell system (RPMI 1640110% Foetal
Bovine Serum) with reference to its cytotoxic action. Literature data show that artemisinin
can react with Fe2* yielding reactive intermediates leaving artemisinin G as a major end-
product. Our study showed that only a large concentration of Fe2* reacted with
artemisinin in distilled water, phophate-buffered saline (PBS), and RPMI/FBS cell culture
medium (24 h of incubation). Artemisinin was degraded, whereas artemisinin G was
formed. HPLC analysis showed 100% recovery of artemisinin in absence of Fdt in
distilled water, and RPMI/FBS with or without EN2 cells at 37"C for at least 24h.
Artemisinin G could not be detected. In addition, incubation of artemisinin in RPMI/FBS
with or without cells at 37'C for 24h prior to a cytotoxicity assay did not significantly
change its cytotoxic action. Based on these results, we stated that the cytotoxicity to
tumour cells was caused by unchanged artemisinin.
In Chapter 5, we described the cytotoxicity of some artemisinin derivatives
against EN2 tumour cells using the MTT assay. Artemisinin was clearly more cytotoxic
than deoxyartemisinin, which lacks the endoperoxide bridge. Ether-linked dimers of
dihydroartemisinin with defined stereochemistry were found to differ in the extent of the
cytotoxic effect on EN2 cells. The nonsymmetrical dimer was more cytotoxic than the
symmetrical dimer. The nonsymmetrical dimer of dihydrodeoxyartemisinin lacking the
endoperoxide bridges was also effective in the MTT assay, although less cytotoxic than
the dimers of dihydroartemisinin. Similarly, the symmetrical dimer was less effective than
the nonsymmetrical. The results suggested that the endoperoxide bridge was not crucial
for cytotoxicity to the tumour cells, but contributed to the cytotoxic effect associated with
the ether linkage of the dimers. Flow cytometry data indicated that the dimers of
dihydroartemisinin caused an accumulation of the cells in the G,-phase of the cell cycle.
In contrast, artemisinin only caused a slight increase of S-phase cells.
With respect to their cytotoxicity towards Ehrlich ascites tumour cells, the dimers
of dihydroartemisinin may be potential antitumour compounds. An antitumour agent
should not be strongly active to normal cells. Chapter 6 describes the in-vitro cytotoxic
activity of artemisinin and some derivatives against murine bone marrow. This was
determined using a clonogenic assay for committed progenitor cells of the granulocyte-
monocyte lineage (CFU-GM assay). Similar to the cytotoxicity to tumour cells
nonsymmetrical dimers were mor€ toxic than symmetrical dimers. Although artemisinin
was more cytotoxic than deoxyartemisinin, the nonsymmetrical dimer of
dihydroartemisinin and the corresponding endoperoxide-lacking dimer of
dihydrodeoxyartemisinin were equally cytotoxic to CFU-GM cells. Unfortunately, most
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ascites tumour cell line. According to the these in-vitro data, the compounds were more
cytotoxic to normal cells than to tumour cells. However, in-vivo testing might have a
different outcome.
The dimers of dihydroartemisinin were subjected to the National Cancer Institute
drug-screening programme consisting of about sixty human cancer cell lines derived from
nine different tissues. Throughout the whole screen the nonsymmetrical dimer was more
cytotoxic than the symmetrical dimer. The NCI selected our compounds for further in-
vivo testing in mice.
Chapter 7 describes the possibilities for future research. Because the G,
accumulation caused by the dimers of dihydroartemisinin was the most interesting finding
of this thesis, the discussion focusses on the cell cycle to identify molecular targets.
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